Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
Sponsor: Georgetown University
Terminated
Lack of accrual
A PHASE1 clinical study on Homologous Recombination Deficiency and Solid Tumor, Adult, this trial is terminated or withdrawn. The trial is conducted by Georgetown University and has accumulated 16 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Nov 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 11 earlier versions
-
Feb 2023 — Nov 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Oct 2021 — Sep 2022 [monthly]
Recruiting PHASE1
-
Mar 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jun 2019 — Mar 2020 [monthly]
Recruiting PHASE1
-
Sep 2018 — Jun 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2017 — Nov 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Georgetown University
- Oregon Health and Science University
- Tesaro, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .